Oral Methylphenidate Treatment of an Adolescent ADHD Rat Model Does Not Alter Cocaine-Conditioned Place Preference during Adulthood: A Negative Report-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

Oral Methylphenidate Treatment of an Adolescent ADHD Rat Model Does Not Alter Cocaine-Conditioned Place Preference during Adulthood: A Negative Report

Oral Methylphenidate Treatment of an Adolescent ADHD Rat Model Does Not Alter Cocaine-Conditioned Place Preference during Adulthood: A Negative Report

ES评分 0 浏览量：617 下载量：0

全文阅读下载引用收藏

DOI	10.20900/jpbs.20190021
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2019, 4(6)
作者	Yanli Zhang-James,David R. Lloyd,Michael L. James,Lina Yang,Jerry B. Richards,Stephen V. Faraone*,
作者单位
Abstract	The stimulant, methylphenidate (MPH), is commonly used to treat attention deficit hyperactivity disorder (ADHD) and has been increasingly prescribed for school age children and adolescents. Concerns regarding its long-term effects on later substance use disorders (SUDs) have been raised. Previous animal studies have produced contradictory results regarding whether early exposure to MPH increases or protects against SUD in adulthood. The goal of our study was to determine if clinically relevant doses of MPH during adolescence alter cocaine responsiveness in adulthood in a rat model of ADHD, the spontaneous hypertensive rat (SHR). We pretreated SHRs with saline or MPH (2.5 mg/kg once or twice day) via oral gavage during their dark cycle from postnatal day 35 (p35) to p44. Adult rats (p80) were assessed in an eight-session cocaine-conditioned place preference test (CPP). Four doses of cocaine were administered via intraperitoneal injection (i.p.) during the conditioning sessions: 1, 5, 10 and 20 mg/kg. Once per day MPH treatment had a small sensitizing effect on baseline general locomotor activity in a novel environment at p80 as well as a limited suppressive effect on reward-specific locomotor activity as measured by the decreased preference to enter the cocaine-paired chamber. This treatment did not have any effect on the amount of time that rats chose to spend in the cocaine-paired chamber. Twice per day MPH treatment had no effect on locomotion or drug-preference. Our results suggest that MPH treatment of ADHD rats during adolescence does not alter preference for cocaine in adulthood.
KeyWord	methylphenidate; ADHD; cocaine; conditioned place preference; locomotion
基金项目
页码	-

参考文献
相关文献

1.Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353-64.

2.Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-65.

3.Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255-70.

4.Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry. 2003;160(11):1909-18.

5.Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav. 2001;68(3):611-27.

6.Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 2008;165(5):604-9.

7.Faraone SV, Upadhyaya HP. The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. J Clin Psychiatry. 2007;68(11):e28.

8.Faraone SV, Rostain AL, Montano CB, Mason O, Antshel KM, Newcorn JH. Systematic Review: Nonmedical Use of Prescription Stimulants: Risk Factors, Outcomes, and Risk Reduction Strategies. J Am Acad Child Adolesc Psychiatry. 2020;59(1):100-12.

9.Burton CL, Nobrega JN, Fletcher PJ. The effects of adolescent methylphenidate self-administration on responding for a conditioned reward, amphetamine-induced locomotor activity, and neuronal activation. Psychopharmacology. 2010;208(3):455-68.

10.Faraone SV, Wilens TE. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry. 2007;68(Suppl 11):15-22.

11.Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179-85.

12.Winters KC, Lee S, Botzet A, Fahnhorst T, Realmuto GM, August GJ. A Prospective Examination of the Association of Stimulant Medication History and Drug Use Outcomes among Community Samples of ADHD Youths. J Child Adolesc Subst Abuse. 2011;20(4):314-29.

13.Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008;165(5):597-603.

14.Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013;52(3):250-63.

15.Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 2013;70(7):740-9.

16.Hammerness P, Joshi G, Doyle R, Georgiopoulos A, Geller D, Spencer T, et al. Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate. J Pediatr. 2013;162(1):22-7.e2.

17.Hammerness P, Petty C, Faraone SV, Biederman J. Do Stimulants Reduce the Risk for Alcohol and Substance Use in Youth With ADHD? A Secondary Analysis of a Prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate. J Atten Disord. 2017;21(1):71-7. doi: 10.1177/1087054712468051

18.Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999;104(2):e20.

19.Schoenfelder EN, Faraone SV, Kollins SH. Stimulant treatment of ADHD and cigarette smoking: a meta-analysis. Pediatrics. 2014;133(6):1070-80.

20.Tamm L, Trello-Rishel K, Riggs P, Nakonezny PA, Acosta M, Bailey G, et al. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder. J Subst Abuse Treat. 2013;44(2):224-30.

21.Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry. 2011;50(9):903-14.

22.Groenman AP, Oosterlaan J, Rommelse N, Franke B, Roeyers H, Oades RD, et al. Substance use disorders in adolescents with attention deficit hyperactivity disorder: a 4-year follow-up study. Addiction. 2013;108(8):1503-11.

23.Andersen SL, Arvanitogiannis A, Pliakas AM, LeBlanc C, Carlezon WA Jr. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci. 2002;5(1):13-4.

24.Carlezon WA Jr, Mague SD, Andersen SL. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry. 2003;54(12):1330-7.

25.Mague SD, Andersen SL, Carlezon WA Jr. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry. 2005;57(2):120-5.

26.Augustyniak PN, Kourrich S, Rezazadeh SM, Stewart J, Arvanitogiannis A. Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder. Behav Brain Res. 2006;167(2):379-82.

27.Brandon CL, Marinelli M, Baker LK, White FJ. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology. 2001;25(5):651-61.

28.Crawford CA, Villafranca SW, Cyr MC, Farley CM, Reichel CM, Gheorghe SL, et al. Effects of early methylphenidate exposure on morphine- and sucrose-reinforced behaviors in adult rats: relationship to dopamine D2 receptors. Brain Res. 2007;1139:245-53.

29.Vendruscolo LF, Izidio GS, Takahashi RN, Ramos A. Chronic methylphenidate treatment during adolescence increases anxiety-related behaviors and ethanol drinking in adult spontaneously hypertensive rats. Behav Pharmacol. 2008;19(1):21-7.

30.Harvey RC, Sen S, Deaciuc A, Dwoskin LP, Kantak KM. Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function. Neuropsychopharmacology. 2011;36(4):837-47.

31.Dafny N, Yang PB. The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull. 2006;68(6):393-405.

32.Kuczenski R, Segal DS. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol Psychiatry. 2005;57(11):1391-6.

33.Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther. 1999;66(3):295-305.

34.Patrick KS, Mueller RA, Gualtieri CT, Breese GR. Pharmacokinetics and actions of methylphenidate. In: Meltzer HY, editor. Psychopharmacology: The third generation of progress. New York (US): Raven Press; 1987. p. 1387-95.

35.Patrick KS, Ellington KR, Breese GR. Distribution of methylphenidate and p-hydroxymethylphenidate in rats. J Pharmacol Exp Ther. 1984;231(1):61-5.

36.Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci. 2002;22(16):7264-71.

37.Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, et al. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther. 1983;226(2):382-6.

38.Aoyama T, Kotaki H, Sawada Y, Iga T. Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats. Psychopharmacology. 1996;127(2):117-22.

39.Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, et al. Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther. 2000;295(1):51-7.

40.Gaytan O, Yang P, Swann A, Dafny N. Diurnal differences in sensitization to methylphenidate. Brain Res. 2000;864(1):24-39.

41.Gaytan O, Ghelani D, Martin S, Swann A, Dafny N. Methylphenidate: diurnal effects on locomotor and stereotypic behavior in the rat. Brain Res. 1997;777(1-2):1-12.

42.Amini B, Yang PB, Swann AC, Dafny N. Differential locomotor responses in male rats from three strains to acute methylphenidate. Int J Neurosci. 2004;114(9):1063-84.

43.Yang PB, Amini B, Swann AC, Dafny N. Strain differences in the behavioral responses of male rats to chronically administered methylphenidate. Brain Res. 2003;971(2):139-52.

44.Myers MM, Musty RE, Hendley ED. Attenuation of hyperactivity in the spontaneously hypertensive rat by amphetamine. Behav Neural Biol. 1982;34(1):42-54.

45.Arnsten AF. Stimulants: Therapeutic Actions in ADHD. Neuropsychopharmacology. 2006;31(11):2376-83.

46.Dela Pena I, Lee JC, Lee HL, Woo TS, Lee HC, Sohn AR, et al. Differential behavioral responses of the spontaneously hypertensive rat to methylphenidate and methamphetamine: lack of a rewarding effect of repeated methylphenidate treatment. Neurosci Lett. 2012;514(2):189-93.

47.Dela Pena I, Kim BN, Han DH, Kim Y, Cheong JH. Abuse and dependence liability analysis of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder (ADHD): what have we learned? Arch Pharm Res. 2013;36(4):400-10.

48.Soeters HS, Howells FM, Russell VA. Methylphenidate does not increase ethanol consumption in a rat model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Metab Brain Dis. 2008;23(3):303-14.

49.Vendruscolo LF, Izidio GS, Takahashi RN. Drug reinforcement in a rat model of attention deficit/hyperactivity disorder--the Spontaneously Hypertensive Rat (SHR). Curr Drug Abuse Rev. 2009;2(2):177-83.

50.Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol. 2007;12(3-4):227-462.

51.Yang L, Faraone SV, Zhang-James Y. Autism spectrum disorder traits in Slc9a9 knock-out mice. Am J Med Genet B. 2016;171B(3):363-76.

52.Zhang-James Y, Yang L, Middleton FA, Yang L, Patak J, Faraone SV. Autism-related behavioral phenotypes in an inbred rat substrain. Behav Brain Res. 2014;269:103-14.

53.Zhang-James Y, Middleton FA, Faraone SV. Genetic architecture of Wistar-Kyoto rat and spontaneously hypertensive rat substrains from different sources. Physiol Genom. 2013;45(13):528-38.

54.Leffa DT, Panzenhagen AC, Salvi AA, Bau CHD, Pires GN, Torres ILS, et al. Systematic review and meta-analysis of the behavioral effects of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2019;100:166-79.

引用本文

Yanli Zhang-James,David R. Lloyd,Michael L. James,Lina Yang,Jerry B. Richards,Stephen V. Faraone*. Oral Methylphenidate Treatment of an Adolescent ADHD Rat Model Does Not Alter Cocaine-Conditioned Place Preference during Adulthood: A Negative Report, Journal of Psychiatry and Brain Science. 2019; 4; (6). https://doi.org/10.20900/jpbs.20190021.

文献评论

相关学者

相关机构